The Medical Letter on Drugs and Therapeutics
Crisaborole (Eucrisa) for Atopic Dermatitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved crisaborole 2% ointment (Eucrisa – Pfizer) for topical treatment of mild to moderate atopic dermatitis in patients ≥2 years old. It is the first phosphodiesterase type-4 (PDE4) inhibitor to be approved in the US for this indication.

ATOPIC DERMATITIS — Atopic dermatitis (also known as atopic eczema) is a chronic pruritic inflammatory skin disease that commonly presents in infancy or early childhood and is frequently associated with other atopic disorders such as allergic rhinitis and asthma. It has a relapsing course, often improving by adolescence. In infants, atopic dermatitis typically involves the face, scalp, and extensor surfaces of the limbs. In older patients, it characteristically involves the flexural areas.

STANDARD TREATMENT — Application of moisturizers, emollients, and barrier creams can reduce the need for pharmacologic therapy. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Crisaborole (Eucrisa) for Atopic Dermatitis
Article code: 1515b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian